The stock of Elicio Therapeutics Inc. (ELTX) has gone down by -35.93% for the week, with a -43.83% drop in the past month and a -43.68% drop in the past quarter. The volatility ratio for the week is 10.99%, and the volatility levels for the past 30 days are 7.60% for ELTX. The simple moving average for the last 20 days is -43.57% for ELTX’s stock, with a simple moving average of -37.16% for the last 200 days.
Is It Worth Investing in Elicio Therapeutics Inc. (NASDAQ: ELTX) Right Now?
ELTX has 36-month beta value of 0.61. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ELTX is 7.63M, and currently, short sellers hold a 0.99% ratio of that float. The average trading volume of ELTX on June 28, 2024 was 46.16K shares.
ELTX) stock’s latest price update
The stock price of Elicio Therapeutics Inc. (NASDAQ: ELTX) has dropped by -37.88 compared to previous close of 6.89. Despite this, the company has seen a fall of -35.93% in its stock price over the last five trading days. investorplace.com reported 2024-06-28 that Elicio Therapeutics (NASDAQ: ELTX ) stock is falling on Friday after the clinical-stage biotechnology company announced a proposed public offering. Elicio Therapeutics has announced its plans for a public offering that will include shares of ELTX stock, warrants to purchase additional shares and pre-funded warrants.
ELTX Trading at -49.72% from the 50-Day Moving Average
After a stumble in the market that brought ELTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.62% of loss for the given period.
Volatility was left at 7.60%, however, over the last 30 days, the volatility rate increased by 10.99%, as shares sank -43.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.14% lower at present.
During the last 5 trading sessions, ELTX fell by -36.15%, which changed the moving average for the period of 200-days by -50.81% in comparison to the 20-day moving average, which settled at $7.42. In addition, Elicio Therapeutics Inc. saw -48.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELTX starting from Chudnovsky Yekaterina, who purchase 1,213,000 shares at the price of $5.81 back on Dec 22 ’23. After this action, Chudnovsky Yekaterina now owns 1,915,639 shares of Elicio Therapeutics Inc., valued at $7,047,530 using the latest closing price.
Stock Fundamentals for ELTX
The total capital return value is set at -2.06. Equity return is now at value -175.11, with -117.72 for asset returns.
Based on Elicio Therapeutics Inc. (ELTX), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -5.5. The debt to equity ratio resting at 1.37. The interest coverage ratio of the stock is -50.71.
Currently, EBITDA for the company is -23.28 million with net debt to EBITDA at 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.37.
Conclusion
To put it simply, Elicio Therapeutics Inc. (ELTX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
